Summit Therapeutics Inc. (SMMT) financials

Summit Therapeutics Inc. (SMMT) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2024, Summit Therapeutics Inc. reported revenue of $0, net income of -$221M, diluted EPS of -$0.31 and free cash flow of -$142M.

Revenue (fiscal 2024)

$0

Net income (fiscal 2024)

-$221M

Diluted EPS (fiscal 2024)

-$0.31

Free cash flow (fiscal 2024)

-$142M

Summit Therapeutics Inc. files with the U.S. Securities and Exchange Commission under CIK 0001599298, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.